Immatics N.V. (IMTX) — SEC Filings

Overview

Immatics N.V. (IMTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 17, 2026: Immatics N.V. filed a Form 6-K on April 17, 2026, reporting information as a foreign issuer. The filing includes documents such as the 6-K form itself, Exhibit 99.1, and a graphic image. The company's business address is Paul Ehrlich-Strasse 15, Tubingen, Germany.

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 34 neutral. The dominant filing sentiment for Immatics N.V. is neutral.

Filing Type Overview

Immatics N.V. (IMTX) has filed 27 6-K, 2 20-F, 2 SC 13G, 4 SC 13G/A, 1 SC 13D/A, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• Immatics N.V. Files 6-K Report — 6-K · Apr 17, 2026 Risk: low
  Immatics N.V. filed a Form 6-K on April 17, 2026, reporting information as a foreign issuer. The filing includes documents such as the 6-K form itself, Exhibit
• Immatics N.V. Updates IMA203CD8 Trial Data — 6-K · Dec 11, 2025 Risk: medium
  On December 11, 2025, Immatics N.V. released updated Phase 1a clinical trial data for its PRAME cell therapy, IMA203CD8. The data, with a cutoff of October 27,
• Immatics N.V. Completes Share Offering — 6-K · Dec 8, 2025 Risk: medium
  On December 8, 2025, Immatics N.V. completed a public offering of 12,500,000 ordinary shares. This offering was conducted under an underwriting agreement with J
• Immatics N.V. Reports Q3 2025 Financials and Business Update — 6-K · Nov 17, 2025 Risk: low
  Immatics N.V. filed an interim report on November 17, 2025, detailing its financial results and business updates for the three- and nine-month periods ending Se
• 6-K Filing — 6-K · Nov 12, 2025
• Immatics Appoints Amie Krause as Chief People Officer — 6-K · Oct 27, 2025 Risk: low
  Immatics N.V. announced on October 27, 2025, the appointment of Amie Krause as its new Chief People Officer, effective immediately. Ms. Krause brings over 20 ye
• Immatics N.V. Updates Uveal Melanoma Trial Data — 6-K · Oct 20, 2025 Risk: medium
  On October 20, 2025, Immatics N.V. released updated Phase 1b clinical trial data for 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell
• Immatics Appoints Venkat Ramanan as CFO — 6-K · Oct 1, 2025 Risk: low
  Immatics N.V. announced on October 1, 2025, the appointment of Venkat Ramanan as its new Chief Financial Officer, effective immediately. Ramanan brings over 25
• Immatics N.V. Files Q2 2025 6-K Report — 6-K · Aug 13, 2025 Risk: medium
  Immatics N.V. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the second quarter of 2025, detailing expenses such
• Immatics N.V. Shareholders Approve 2024 Accounts at AGM — 6-K · Jun 18, 2025 Risk: low
  On June 18, 2025, Immatics N.V. held its Annual General Meeting of Shareholders (AGM). Shareholders approved all agenda items, including the adoption of the sta
• Immatics N.V. Updates IMA203 Trial Data — 6-K · Jun 2, 2025 Risk: medium
  Immatics N.V. announced on June 2, 2025, updated Phase 1b clinical trial data for its IMA203 PRAME cell therapy. The data, with a cutoff of April 7, 2025, invol
• Immatics N.V. Reports Q1 2025 Financials and Business Update — 6-K · May 13, 2025 Risk: low
  On May 13, 2025, Immatics N.V. filed a Form 6-K to report its interim results for the three-month period ended March 31, 2025. The filing includes an interim re
• Immatics N.V. Files 2024 Annual Report — 20-F · Mar 27, 2025 Risk: medium
  Immatics N.V. filed its 20-F annual report for the fiscal year ending December 31, 2024. The company, based in Tübingen, Germany, is involved in biological prod
• Immatics N.V. Reports 2024 Financials and Updates — 6-K · Mar 27, 2025 Risk: low
  On March 27, 2025, Immatics N.V. released its full-year 2024 financial results and provided corporate updates. The company also made an updated investor present
• Immatics N.V. Updates Investor Presentation — 6-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Immatics N.V. released an updated investor presentation. This filing is a Form 6-K, which is a report of a foreign private issuer. The pres
• BMS Terminates Immatics Allogeneic Program Collaboration — 6-K · Dec 13, 2024 Risk: medium
  On December 12, 2024, Bristol Myers Squibb (BMS) informed Immatics N.V. that it is terminating its collaboration agreements related to allogeneic programs. This
• Immatics N.V. Reports Q3 2024 Financials and Business Update — 6-K · Nov 18, 2024 Risk: low
  Immatics N.V. filed a Form 6-K on November 18, 2024, to report its interim financial results for the three- and nine-month periods ended September 30, 2024. The
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 14, 2024
• Immatics N.V. Presents Updated Clinical Data for IMA203 — 6-K · Nov 8, 2024 Risk: medium
  On November 8, 2024, Immatics N.V. reported updated Phase 1b clinical data for ACTengine® IMA203, showing positive results with a data cutoff of August 23, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Perceptive Advisors Amends Immatics Stake — SC 13D/A · Oct 17, 2024 Risk: medium
  Perceptive Advisors LLC, through its fund Perceptive Life Sciences Master Fund, Ltd., has filed an amendment (No. 1) to its Schedule 13D for Immatics N.V., date
• Immatics N.V. Completes Share Offering — 6-K · Oct 15, 2024 Risk: medium
  On October 15, 2024, Immatics N.V. completed an offering of 16,250,000 ordinary shares. The offering was conducted through an underwriting agreement with Jeffer
• Immatics N.V. Updates on IMA203 Cell Therapy for Melanoma — 6-K · Oct 10, 2024 Risk: medium
  On October 10, 2024, Immatics N.V. announced updated Phase 1b clinical data for its ACTengine® IMA203 TCR-T therapy targeting PRAME in melanoma patients. The co
• Immatics N.V. Shares Positive Phase 1 Data for IMA401 — 6-K · Sep 16, 2024 Risk: medium
  On September 16, 2024, Immatics N.V. announced proof-of-concept clinical data from its Phase 1 trial for TCER® IMA401. This novel bispecific T cell engager targ
• Immatics N.V. Files Q2 2024 6-K Report — 6-K · Aug 13, 2024 Risk: low
  Immatics N.V. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024, detailing expenses such
• Immatics N.V. Appoints Alise Reicin to Board — 6-K · Jul 31, 2024 Risk: low
  On July 29, 2024, Immatics N.V. appointed Alise Reicin as a temporary non-executive director to its Board of Directors. This appointment is effective immediatel
• Immatics N.V. Shareholders Approve 2023 Accounts and Discharge Boards — 6-K · Jun 20, 2024 Risk: low
  On June 20, 2024, Immatics N.V. held its Annual General Meeting of Shareholders (AGM). Shareholders approved all agenda items, including the adoption of the sta
• Perceptive Advisors Files SC 13D for Immatics N.V. — SC 13D · Jun 6, 2024 Risk: medium
  On June 6, 2024, Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. filed a Schedule 13D regarding Immatics N.V. The filing indicates a change in ben
• Immatics N.V. Schedules Annual General Meeting for June 20 — 6-K · Jun 3, 2024 Risk: low
  Immatics N.V. announced on June 3, 2024, that it has made available a convening notice for its annual general meeting. The meeting is scheduled to occur on June
• Immatics N.V. Reports Q1 2024 Interim Results — 6-K · May 14, 2024 Risk: low
  Immatics N.V. filed a Form 6-K on May 14, 2024, to report its interim results for the three-month period ended March 31, 2024. The filing includes an interim re
• Immatics N.V. Files 20-F Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 21, 2024 Risk: medium
  Immatics N.V. (IMTX) filed a Foreign Annual Report (20-F) with the SEC on March 21, 2024. Immatics N.V. filed its annual report on Form 20-F for the fiscal year
• Immatics N.V. Reports 2023 Financial Results — 6-K · Mar 21, 2024 Risk: low
  On March 21, 2024, Immatics N.V. announced its full-year 2023 financial results and provided corporate updates. The company filed a Form 6-K report detailing th
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Wellington Management Amends Immatics N.V. Stake (SC 13G/A) — SC 13G/A · Feb 8, 2024 Risk: low
  Wellington Management Group LLP filed an amended SC 13G/A on February 8, 2024, indicating a change in their beneficial ownership of Immatics N.V. (NASDAQ: IMTX)
• ATHOS KG Amends Immatics N.V. (IMTX) Stake Filing — SC 13G/A · Feb 7, 2024
  ATHOS KG, a German investment firm, has filed an amended SC 13G/A for Immatics N.V. (NASDAQ: IMTX) as of December 31, 2023. This filing indicates that ATHOS KG
• Immatics N.V. Completes 18.3M Share Offering on Jan 22 — 6-K · Jan 22, 2024
  Immatics N.V. completed an offering of 18,313,750 ordinary shares on January 22, 2024, through an underwriting agreement with Jefferies LLC, BofA Securities, In

Related Companies

BMY

Frequently Asked Questions